Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
David G MutchAthina VoulgariXian Marissa ChenWilliam H BradleyAna OakninJosé Alejandro Perez FidalgoFernando Galvez MontosaAntonio Casado HerraezRobert W HollowayMatthew A PowellMalgorzata NowickaGabriele SchaeferMark MerchantYibing YanPublished in: Cancer (2024)
Chemotherapy-free doublet and triplet therapy demonstrated encouraging activity, including among patients who had BRCA wild-type, HRDsig-positive or HRDsig-negative PSROC harboring NF1 or MKNK1 mutations.